Healthpoint Acquires Topical Collagenase Business
Healthpoint (Fort Worth, Tex) and BioSpecifics Technologies Corp. (Lynbrook, NY) announce the sale of BioSpecifics’ topical collagenase business. As part of the agreement, Healthpoint’s affiliate will assume ownership and operation of the BioSpecifics’ manufacturing facility in Curaçao and other assets owned by BioSpecifics’ affiliate, Advance Biofactures Corporation.
The deal will involve $8 million in upfront cash to BioSpecifics and an additional payment for future services to be provided by Advance Biofactures Corporation. The deal terms also include the potential for BioSpecifics’ to benefit from an earn-out based on sales.
Healthpoint’s affiliate plans to invest $1.5 million to upgrade the newly acquired manufacturing facility, which currently produces Collagenase ABC, an enzyme derived from the fermentation of the bacterium Clostridium histolyticum.
For more information, visit http://www.healthpoint.com.
Worldwide Organization to Recognize Swiss-American Products for Development of Elta Proteases™ Swiss-American Products, Inc. (Dallas, Tex) has developed a product line that will be the focus of a presentation during the upcoming Wound Healing Society meeting to be held May 14–17, 2006, in Scottsdale, Ariz.
The presentation, titled “Elta Hydrovase Wound Dressing Components Degrade Proteins Detrimental to Wound Healing,” will provide information from a recent study by the University of Florida on a proprietary blend of protease enzymes developed by Swiss-American. The study results show that the blend helps speed the healing process for a wide variety of wounds, including pressure ulcers, sores caused by incontinence, and wounds resulting from injury or certain diseases that impact the skin.
Visit http://www.elta.net for more information.
RegeneRx Updates Website RegeneRx Biopharmaceuticals, Inc. (Bethesda, Md) announces that it has updated its website at www.regenerx.com. In addition to updated historical and graphical information, the new site is easier to navigate and includes new content pertaining to the company’s technology platform and phase II clinical trials.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43-amino acid peptide, under an exclusive worldwide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore, RegeneRx is developing TB4 as a therapeutic platform. RegeneRx holds over 50 worldwide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair; cardiac and neurological injuries; and septic shock. RegeneRx is currently sponsoring 3 phase II chronic dermal wound healing clinical trials and has additionally targeted ophthalmic and cardiac trials in 2006 as part of its ongoing clinical development program.
For more information, visit http://www.regenerx.com.
Biopharmaceutical Company will Explore Use of Gaseous Nitric Oxide for Treatment of Chronic Wounds VIASYS Healthcare Inc. (Conshohocken, Pa) recently completed a transaction in which it formed Theranox Inc., a company dedicated to exploring medical applications of topically applied gaseous nitric oxide (gNO). Quaker BioVentures and NewSpring Capital, both Philadelphia-based venture capital firms, jointly led the initial financing of Theranox, and VIASYS participated in the financing as an investor. VIASYS owns or controls an extensive patent portfolio for the topical use of gNO and has exclusively licensed these patents to Theranox for use in this field. The license agreement provides for milestone payments, technology access fees, and royalty payments to VIASYS.
Theranox, Inc. is a venture-backed start-up company dedicated to exploring medical applications of topically applied gNO. Theranox intends to conduct clinical trials and commercialize gNO for the treatment of nonhealing chronic wounds and for the treatment of other topical medical problems, such as post-surgical infections.
Visit http://www.viasyshealthcare.com for more information.
|
